Thursday, November 03, 2016 1:48:49 PM
Entry into a Material Definitive Agreement.
On September 26, 2016, BioRestorative Therapies, Inc. (the "Company") sold to John M. Desmarais, a director and principal stockholder of the Company, 80,000 shares of common stock of the Company at a purchase price of $3.00 per share, or an aggregate purchase price of $240,000. In consideration of the purchase, the Company issued to Mr. Desmarais a five year warrant to purchase 80,000 shares of common stock of the Company at an exercise price of $4.00 per share and extended the expiration dates of warrants held by Mr. Desmarais for the purchase of 444,444 and 400,000 shares of common stock of the Company for a period of one year to November 18, 2017 and March 18, 2018, respectively.
Item 3.02.
Unregistered Sales of Equity Securities .
Between, August 30, 2016 and September 16, 2016, the Company issued an aggregate of 24,390 shares of common stock of the Company in exchange for outstanding indebtedness in the aggregate amount of $26,315, inclusive of accrued and unpaid interest.
Between September 3, 2016 and September 14, 2016, the Company issued an aggregate of 25,000 shares of common stock of the Company at a purchase price of $3.00 per share. In consideration of the share purchases, the Company issued to the subscribers five year warrants for the purchase of an aggregate of 25,000 shares of common stock of the Company at an exercise price of $4.00 per share.
On September 8, 2016, the Company issued 11,000 shares of common stock of the Company at a purchase price of $2.73 per share. In consideration of the share purchase, the Company issued to the subscriber a five year warrant for the purchase of 11,000 shares of common stock of the Company at an exercise price of $4.00 per share.
See Item 1.01 above with respect to the issuance of 80,000 shares of common stock of the Company and warrants for the purchase of 80,000 shares of common stock of the Company.
For each of the securities issuances, the Company relied upon Section 4(a)(2) of the Securities Act of 1933, as amended (the "Act"), as transactions by an issuer not involving any public offering or Section 3(a)(9) of the Act as a security exchanged by an issuer with its existing security holders exclusively where no commission or other remuneration is paid or given directly or indirectly for soliciting such exchange. For each such transaction, the Company did not use general solicitation or advertising to market the securities, the securities were offered to a limited number of persons, the investors had access to information regarding the Company (including information contained in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, Quarterly Reports on Form 10-Q for the periods ended March 31, 2016 and June 30, 2016, and Current Reports on Form 8-K filed with the Securities and Exchange Commission and press releases made by the Company), and management of the Company was available to answer questions from prospective investors. The Company reasonably believes that each of the investors is an accredited investor.
Recent BRTX News
- BioRestorative Therapies to Participate in the 36th Annual ROTH Conference • GlobeNewswire Inc. • 03/11/2024 08:15:00 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 03/06/2024 09:34:22 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/15/2024 09:43:54 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/15/2024 09:40:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:27:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:25:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:23:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:19:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:17:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:13:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/15/2024 09:11:35 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 06:44:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/12/2024 02:26:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 01:00:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/08/2024 09:09:49 PM
- BioRestorative Therapies Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $8.1 Million Gross Proceeds Priced At-the-Market • GlobeNewswire Inc. • 02/06/2024 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 01:00:18 PM
- BioRestorative Therapies Presents Preliminary Clinical Data from Phase 2 Study of BRTX-100 in Chronic Lumbar Disc Disease • GlobeNewswire Inc. • 02/05/2024 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/01/2024 09:43:48 PM
- BioRestorative Therapies to Present Preliminary BRTX-100 Clinical Data at the Orthopaedic Research Society (ORS) 2024 Annual Meeting • GlobeNewswire Inc. • 02/01/2024 12:30:00 PM
- BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program • GlobeNewswire Inc. • 12/12/2023 02:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/05/2023 09:32:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/01/2023 10:04:17 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 11/15/2023 09:14:35 PM
- BioRestorative Therapies, Inc. to Participate at the ROTH MKM Healthcare Opportunities Conference October 12, 2023 in New York City • GlobeNewswire Inc. • 10/09/2023 04:10:00 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM